Brief: Cizzle Biotechnology and Cizzle Bio Achieve CLIA Validation
BRIEF-Cizzle Biotechnology and Cizzle Bio Achieve CLIA Validation Oct 15 (Reuters) - Cizzle Biotechnology Holdings PLC CIZ.L:
CIZZLE BIOTECHNOLOGY - UPDATE ON LAUNCH OF LUNG CANCER TEST IN USA
CIZZLE BIOTECHNOLOGY - REMAINING $1.81 MILLION GUARANTEED ADVANCE PAYMENTS TO BE PAID BY DEC 31, 2027
CIZZLE BIOTECHNOLOGY - REALIGNS GUARANTEED ROYALTY PAYMENTS TO DECEMBER 2027; OPTION TO CONVERT TO BIO STOCK
Source text: ID:nRSO0205Za
Further company coverage: CIZ.L
((Reuters.Briefs@thomsonreuters.com))
Recent news on Cizzle Biotechnology Holdings
See all newsRCS - Cizzle Biotechnology - Cizzle Shortlisted for One Nucleus Award 2026
Brief: Cizzle Biotechnology and Cizzle Bio Achieve CLIA Validation
Cizzle Biotechnology - Update on Launch of Lung Cancer Test in USA
Cizzle Biotechnology - Interim Results
Cizzle Biotechnology - Laboratory Expansion to Accelerate Sales in USA